A study comparing the usage of monoclonal and polyclonal antibodies specific for immunoglobulin light and heavy chains was performed on frozen-tissue sections of 30 B-cell non-Hodgkin's lymphomas. In 16 cases, monotypic staining for an immunoglobulin light chain was demonstrated with monoclonal antibodies using a three-step avidin-biotin peroxidase complex (ABC) method; 13 cases were positive for kappa. In 14 cases, no immunoglobulin light-chain production was demonstrated. Repeat staining of 11 of these 14 cases with polyclonal anti-sera by a direct immunoperoxidase method demonstrated monotypic staining for light chain in 10 cases, 9 of which were positive for lambda. In 22 of 30 non-Hodgkin's lymphomas, an immunoglobulin heavy chain was identified using monoclonal anti-sera. In eight cases, however, no heavy chain was found. 
SINCE KOHLER AND MILSTEIN
19 first reported the hybridoma technic in 1975, a large number of monoclonal antibodies have been produced for diagnostic purposes. They are now used extensively in diagnostic immunohistochemistry and have been used for the detection of serologic tumor markers, for in vivo tumor localization, and in tumor immunotherapy. 7 Most non-Hodgkin's lymphomas in the United States are B-cell neoplasms. The frozen section immunoperoxidase technic is a reliable and convenient way to visualize in situ monotypic immunoglobulin production by neoplastic cells of B-cell lymphomas. 14 Using polyclonal anti-sera against specific human immunoglobulin heavy and light chains, we have experienced results both satisfactory and comparable to those reported by others. Background staining, however, has hindered interpretation of the immunoperoxidase-stained slides in some cases. Recently, in an attempt to decrease background staining, we substituted monoclonal antibodies for polyclonal anti-sera in our procedure. Subsequently, we obtained an unexpected increase in the number of lymphomas where immunoglobulin production could not be demonstrated. Concomitant with this, we observed an unexpectedly low percentage of lambda-producing lymphomas and an unexpectedly high ratio of kappa:lambda-staining cells in lymph nodes not involved by lymphoma. Repeat immunoperoxidase staining using polyclonal anti-sera demonstrated monotypic staining of lymphoma cells, in most cases for lambda, in most cases in which staining with monoclonal reagents had been negative. Cossman and associates 6 previously had observed the lack of sensitivity of an anti-lambda monoclonal antibody. Their observation was reported in an abstract, the major intention of which was to convey the utility of the study of immunoglobulin messenger RNA to determine the monoclonality of B-cell lymphomas. We encountered a somewhat higher frequency of false nega- Case   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30   Histology   NPDL  NPDL  NPDL  NPDL  NPDL  NMC  NMC  NMC  NMC  NLC  NLC  NLC  NLC  DWDL  DWDL  DWDL  DWDL  DWDL  DWDL  DWDL  DWDL  DMC  DMC  DLC  DLC  DLC  DLC  DLC  DLC  Burkitt's   Total Positive Cases  Total Cases Monoclonal Antibodies tive results using anti-lambda monoclonal antibodies of a different source than did these authors. In addition, we observed false negative results for kappa in one case and for immunoglobulin heavy chain in a few cases. We feel that greater awareness of this potential diagnostic pitfall with the use of monoclonal antibodies to immunoglobulin as diagnostic reagents is needed. In this regard, a report of our findings is given. 
Materials and Methods
Thirty consecutively accessioned lymph node biopsies demonstrating B-cell non-Hodgkin's lymphoma and on which immunoperoxidase studies were done form the basis of this article. Histologic subclassification was done using a system modified from Rappaport. 21 The results are shown in Table 1 . Four-micron-thick cryostat sections were cut from fresh lymph node tissue and fixed in acetone for 5 seconds, air dried, and stored at -70 °C. In certain cases, a piece of tissue was covered in OCT, snap frozen in isopentane and dry ice, and stored at -70 °C. Before staining, sections were postfixed in cold acetone for 10 minutes and transferred to modified phosphate-buffered saline (PBS). Excess PBS was drained, and slides were covered with normal horse serum for 20 minutes. Sections of all lymphoma cases were covered for one hour with unconjugated monoclonal antibodies directed against immunoglobulin heavy or light chains (Miles. Scientific, Naperville, IL) at the following dilutions: kappa and lambda, 1:8,000; IgG, 1:4,000; and IgM, 1:1,000. In addition, monoclonal antibodies directed against T-cell antigens (Leu-1 and Leu-4; Becton-Dickinson, Mountain View, CA) and T-cell subsets (OKT-4 and OKT-8, Ortho Diagnostic Systems, Raritan, NJ) were used. In nine cases, B-cell derivation was confirmed using B-1 (Coulter International, Hialeah, FL) monoclonal antibodies. After two washes in PBS, tissue sections were incubated with fresh 3-amino-9-ethylcarbazole for 30 minutes, washed in distilled water, and counterstained with Gill's hematoxylin. The presence of one or more positively stained lymphocytes was required to assure validity of a negative staining result.
In cases in which immunoglobulin light-chain or heavychain production was not identified and in which additional frozen tissue section slides or frozen tissue was available, staining was repeated by the direct immunoperoxidase method using polyclonal peroxidase-conjugated anti-sera raised in goats (Tago, Burlingame, CA) at the dilution of 1:75.
Results
Detailed immunostaining findings for both monoclonal and polyclonal antibodies appear in Table 2 . No correlation between histologic and immunoglobulin type was evident.
Immunostaining using monoclonal antibodies was performed in all lymphoma cases and results are summarized in Table 3 . In 16 of 30 B-cell lymphomas, monotypic light-chain production was demonstrated, and 13 cases stained positively for kappa. In 14 lymphomas, no light-chain production was demonstrated. In 22 lymphomas, positive staining of lymphoma cells for immunoglobulin heavy chain was demonstrated; IgM was identified in 17 cases. In eight lymphoma cases, monoclonal antibodies failed to show an immunoglobulin heavy chain. In cases showing no light-or no heavy-chain production using monoclonal antibodies, and in which additional unstained tissue sections or stored frozen tissue were available, immunostaining was repeated using polyclonal antisera. Staining results are summarized in Table 4 . Immunostaining was repeated in 11 of 14 cases in which no light-chain production was found. Nine cases showed monotypic, positive staining for lambda ( Fig. 1) and monotypic kappa light-chain production was demonstrated in one lymphoma (Fig. 2) . Negative staining of tumor cells for immunoglobulin kappa and lambda light chains was observed in one follicular lymphoma (Table  2 ; case 2). Immunostaining was repeated in only three of the eight cases in which no heavy-chain production was demonstrated. Heavy-chain positivity (IgM in two cases and IgG in one) of lymphoma cells was demonstrated in each case.
Discussion
The main advantage of monoclonal over polyclonal antibodies lies in their purity and greater specificity, in their more simple isolation, and in the potential for their unlimited production. 57 ' 24 A growing number of monoclonal anti-sera against cell surface antigens are now available and have been applied to the phenotyping of acute lymphoblastic leukemias and non-Hodgkin's lymphomas. 5 Non-Hodgkin's lymphomas have been investigated using anti-sera to immunoglobulin heavy and light chains in frozen tissue 114, 22 and certain special fixatives (transport media). 4 " Frozen tissue section immunoperoxidase procedures have the advantage of permitting in situ visualization of immunoglobulin and other antigens in lymphoma cells and nonneoplastic cells in lymph nodes, spleen, and other tissues. 16 Recognition of abnormal distribution and morphologic features of positive-staining cells and correlation with routine histology is facilitated.
114, 23 Satisfactory results have been reported with the use of both polyclonal 3,12 ' 4,22 and monoclonal 1, 8 antibodies.
In early 1984, we began using monoclonal antibodies specific for immunoglobulin light and heavy chains and an ABC method to identify immunoglobulin production in non-Hodgkin's lymphomas. This was done in an attempt to decrease the background staining that we were seeing in certain cases studied with polyclonal anti-sera. Monoclonal antibodies did produce a lesser degree of background staining than polyclonal sera, as would be expected from their greater purity. 24 In one-half of our B-cell lymphomas (14 of 30), however, monoclonal antibodies failed to reveal immunoglobulin light-chain and, less commonly, heavy-chain production (8 of 30). B-cell lymphomas not expressing surface immunoglobulin are more unusual than this, however, based on the experience reported in most series.' 214 Furthermore, we also encountered an unexpectedly high percentage of kappa-positive lymphomas (13 kappa-positive vs. 3 lambda-positive lymphomas). Ancelin and associates' found a predominence of lambda-positive lymphomas; Harris and Data 13 have reported a roughly equal number of follicular B-cell lymphomas staining for kappa and lambda light chain; and Doggett and colleagues 8 found only a twofold predominance of kappa-positive lymphomas. When we repeated immunostaining of our negatively staining cases with polyclonal anti-sera, monotypic staining, usually for lambda, was demonstrated. Thus, most lymphomas with monotypic lambda light-chain production showed negative staining when monoclonal anti-lambda antibody was used. The monoclonal anti-kappa antibody was more reliable, although kappa light chain was missed in one lymphoma. In each of three cases with no evidence of heavychain production and in which staining could be repeated with polyclonal anti-sera, a positive staining result was found. Although we experienced decreased background staining with the use of monoclonal antibodies to immunoglobulin light and heavy chains, this benefit was achieved with an unacceptable loss of sensitivity, particularly for the detection of lambda-producing cells.
The question of reliability of monoclonal antibodies has been investigated earlier. Porstmann and associates 20 comparing monoclonal and polyclonal antibodies in enzyme immunoassay for human alpha fetoprotein, emphasized the increased sensitivity of the heterologous antiserum. In immunohistologic studies employing frozen tissue sections, however, monoclonal and polyclonal antibodies usually have given similar results. Hsu and coworkers, 17 comparing anti-kappa monoclonal and polyclonal antibodies in the immunostaining of tonsil sections, and Doggett and co-workers, 8 comparing polyclonal and monoclonal antibodies specific for immunoglobulin light and heavy chains in the immunostaining of 13 large-cell lymphomas, found no significant difference in the staining pattern and distribution of positive cells. Cossman and colleagues, 6 however, observed lack of sensitivity of an anti-lambda monoclonal antibody used to study nonHodgkin's lymphomas. They experienced false negative staining results for lambda in 4 of 18 lambda-positive lymphomas but in none of 16 kappa-positive lymphomas. Similar to their experience, the main problem we encountered using monoclonal antibodies from a different source was failure to detect lambda. We encountered false negative staining in most lambda-positive lymphomas. We also found false negative staining of kappa or heavychain in a few lymphoma cases when monoclonal reagents were used.
Variability of antigenic sites on the immunoglobulin molecule seems a likely explanation for these observations. The epitope or antigenic site of a given antigen or molecule that a monoclonal antibody recognizes comprises merely five to seven amino acids. 2 A particular monoclonal antibody can fail to recognize the antigen to which it is directed, even when it is present if the antigenic site that it recognizes is subject to variability. 518 The Bence-Jones monoclonal urinary protein used to immunize the mouse in the generation of the hybridoma is the product of a clone of myeloma cells and represents a pure population of immunoglobulin molecules. The monoclonal antibody generated reacts with a single antigenic determinant present on the urinary protein. The monoclonal antibody will identify only human immunoglobulin of a class or type (depending on the antibody) possessing the same antigenic determinant as the one recognized on the urinary protein used for immunization. If that determinant is subject to variation, this could explain the failure of monoclonal antibodies to detect immunoglobulins of the specific class or type to which it is directed, even when its presence was demonstrated with class-or type-specific polyclonal antibodies. Furthermore, it is believed that antigenic determinants can appear on tumor cells that differ from the corresponding determinants on normal cells. 318 Immunoglobulins produced by lymphoma cells might have one or more abnormal epitopes. Thus, "abnormal" idiotypic variation is another possible mechanism for the false negative results obtained with monoclonal reagents. Idiotypic variability does not, however, explain entirely the particularly high incidence of negative staining encountered with anti-lambda compared with anti-kappa monoclonal antibodies. Isotypic variation, however, does offer a possible mechanism for this observation. Four isotypes of lambda exist that differ by only a few amino acid substitutions in the constant region and that are present in the serum of all humans. 915 Isotypes of human kappa light chain are not known. 10 Since the Bence-Jones urinary protein would be entirely of one isotype, the monoclonal antibody could conceivably react With the antigenic site on the iambda molecule that determines its isotype and might, therefore, recognize only human lambda of the same isotype as the monoclonal urinary protein. This is but speculation, of course. Proof would require characterization of the Bence-Jones lambda urinary protein, as well as of the different immunoglobulin light chain molecules produced by the lymphomas tested.
Whatever the cause of the decreased sensitivity encountered with monoclonal reagents that we experienced, it is surprising to us that the problem has not been encountered more commonly by others who have reported series of lymphomas studied using monoclonal antibodies to immunoglobulin.
